
|Videos|May 3, 2016
Dr. Abou-Alfa on Emerging PD-L1 Agents in Liver Cancer
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering, discusses what is on the horizon for the use of PD-L1 agents in liver cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































